AI-generated · cited to primary sources · not investment advice · How we research
This investment thesis examines Hims & Hers Health (NYSE: HIMS), a digital healthcare platform focused on making personalized treatments more accessible. The analysis evaluates the company’s business model, management, future growth opportunities, key risks, and potential scenarios to assess whether HIMS can sustain its momentum in the evolving healthcare and telehealth market.
Want this thesis on a stock you own?
Create a free account to prefill a ticker and generate the same cited management, growth, risk, and scenario analysis.
Our verdict on Hims & Hers Health, Inc. Class A Common Stock isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →There is not enough evidence here to say management has generally delivered on its past commitments, because the listed promises are all marked as unclear and mostly describe future plans. The most important promise is the goal of handling a majority of pharmaceutical and over-the-counter orders through its own fulfillment, pharmacy, laboratory, and manufacturing operations, but the evidence does not say whether that has happened. The biggest weakness is that management gives no numerical targets for revenue growth, adjusted EBITDA, earnings, or market share, making it difficult to judge missed goals or quietly changed plans. For now, investors should treat management’s statements as intentions rather than proven guidance and look for clear progress before placing much trust in them.
Management expects to continue focusing on long-term growth by investing in fulfillment, distribution, internal pharmacy, laboratory testing, and peptide manufacturing capabilities, with the goal of fulfilling a majority of pharmaceutical and over-the-counter orders internally. — target: Fulfill a majority of pharmaceutical and over-the-counter customer orders through internal fulfillment capabilities. (+4 more commitments)
“We intend to continue to invest in our fulfillment, distribution, and operating capabilities, including in our wholly-owned pharmacies ... our laboratory testing facilities and our peptide manufacturing facility ... with the goal of fulfilling a majority of our pharmaceutical and over-the-counter customer orders through internal fulfillment capabilities. For example, we are making investments in the expansion of our current Facilities, which are expected to continue for at least the next 12 months.”
Quarterly Report · Jun 2026 · p.42Management intends to expand international operations through acquisitions and continued geographic expansion.
“Expanding our business to attract customers, Providers, and suppliers in countries other than the United States is a core pillar of our long-term growth strategy.”
Quarterly Report · Jun 2026 · p.69Maintain long-term revenue retention from subscribers who remain subscribed for more than two years. (+1 more commitment)
“We expect to retain a significant majority of revenue from Subscribers who maintain a Subscription for more than two years (sometimes referred to by us as “long-term revenue retention”).”
Quarterly Report · Sep 2025 · p.33Achieve long-term operating leverage, with revenue growth outpacing investments in operations and support, and reduce operations and support expense as a percentage of revenue. (+2 more commitments)
“We expect operations and support expenses to increase for the foreseeable future as we continue to invest in our fulfillment and operating capabilities and grow our business, resulting in additional operational efficiencies. As a result, we expect revenue growth to continue to outpace those investments made, leading to a decrease in operations and support expenses as a percentage of revenue over the long term.”
Quarterly Report · Sep 2025 · p.38Continue significant marketing investment to acquire new customers and invest in product offerings and customer experience. (+1 more commitment)
“Additionally, we expect to continue to make significant investments in marketing to acquire new customers and we expect to continue to make investments in product offerings and customer experience.”
Quarterly Report · Sep 2025 · p.34Management expects technology and development expense to increase as it expands the platform, AI capabilities, and new offerings, with long-term stabilization as a percentage of revenue. — target: Technology and development expense expected to stabilize as a percentage of total revenue over the long term. (+4 more commitments)
“We expect these expenses to stabilize over the long term, although it may fluctuate as a percentage of total revenue from period to period due to the timing and amount of these expenses.”
Quarterly Report · Jun 2026 · p.46Management expects continued expansion into new health and wellness specialties. (+3 more commitments)
“We expect to continue to expand into new health and wellness specialties with our offerings.”
Quarterly Report · Jun 2026 · p.42Management expects to continue offering branded GLP-1 medications while limiting access to compounded GLP-1 medications in the U.S. weight-loss offering. (+1 more commitment)
“As a result of the FDA resolving the semaglutide shortage, which has constrained and is expected to continue to constrain our ability to continue providing access to compounded semaglutide on our platform, we expect this metric to decrease in the near term relative to the first half of 2025 and normalize over the long term.”
Quarterly Report · Jun 2025 · p.30Management expects to fund future Eucalyptus deferred and earn-out obligations with cash generated from operations and may issue equity or convertible debt; it also retains the option to settle a significant majority with Class A shares. — target: Up to $683.9 million of deferred payments plus up to $96.6 million of contingent earn-out consideration; significant majority may be settled in shares, subject to a 19.9% Class A share issuance cap. (+4 more commitments)
“The purchase price for accounting purposes was $968.5 million, including cash paid upfront of $225.0 million, deferred payments totaling $683.9 million payable in six quarterly installments through the 18-month anniversary of the closing, and contingent consideration with an acquisition date fair value of $59.6 million. The contingent consideration relates to a potential aggregate earn-out payment of up to $96.6 million, upon achievement of revenue and adjusted EBITDA targets with measurements occurring for each of the 2026, 2027, and 2028 fiscal years. We have the option, at our sole discretion, to settle a significant majority of the deferred consideration and earn-out payments in shares of our Class A common stock, subject to a cap on the aggregate number of shares issuable equal to 19.9% of our issued and outstanding Class A common stock, together with any securities issued or issuable in a financing by us in connection with the acquisition.”
Quarterly Report · Jun 2026 · p.51See whether management delivered on its promises — and where it didn't.
The core online business expanded substantially: nine-month revenue increased 74% year over year, while personalized offerings rose from approximately half of Online Revenue to approximately 70%. This indicates both strong revenue growth and a favorable shift toward personalized treatment plans, although the newer mix reduced gross margin. (5 expanding across 1 engine)
“Revenue was $753.2 million for the three months ended June 30, 2026, compared to $544.8 million for the three months ended June 30, 2025, an increase of $208.4 million, or 38%.”
Quarterly Report · Jun 2026 · p.48The infrastructure moat broadened from a primarily digital platform into a more vertically integrated operating system. The company added manufacturing assets, laboratory testing capability, expanded pharmacies and fulfillment facilities, and invested heavily in physical infrastructure and software. (3 expanding, 1 new)
“The Hims & Hers platforms ... include access to a highly-qualified and technologically-capable provider network, a clinically-focused electronic medical records system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities.”
Quarterly Report · Jun 2026 · p.39Brand investment intensified rather than weakened. Customer acquisition spending increased 49% year over year for the nine-month period, including a Super Bowl campaign, supporting subscriber growth and broader adoption of personalized offerings. The filing does not provide a separate brand-value measure. (5 expanding)
“Our brand is integral to our success. If we fail to effectively maintain, promote, and enhance our brand in a cost-effective manner, our business and competitive advantage may be harmed.”
Quarterly Report · Jun 2026 · p.62Scale expanded materially: subscribers rose 21%, revenue increased 74% for the nine-month period, and the company added manufacturing, pharmacy, fulfillment, and laboratory capabilities. However, the latest quarter showed weaker GAAP operating leverage because operating income fell 47% year over year as investments and higher fulfillment costs grew faster than revenue. (1 shifted, 1 expanding)
“Income from operations was $96.4 million for the nine months ended September 30, 2025, compared to $43.3 million for the nine months ended September 30, 2024... Income from operations was $11.8 million for the three months ended September 30, 2025, compared to $22.4 million for the three months ended September 30, 2024.”
Quarterly Report · Sep 2025 · p.40International exposure expanded through the July 2025 acquisition of Zava, which added operations in the United Kingdom and established entry into Germany, France, and Ireland. However, international operations were still described as not significant for the nine-month period. (1 new, 1 expanding)
“We generated $131.4 million in Rest of the World Revenue for the three months ended June 30, 2026, an increase of $123.8 million, or 1,641%, as compared to $7.5 million for the three months ended June 30, 2025. Growth in Rest of the World Revenue was primarily driven by the geographic expansion from our recent acquisitions, including our acquisition of Eucalyptus.”
Quarterly Report · Jun 2026 · p.39The subscription engine strengthened: subscribers grew 21% and monthly online revenue per average subscriber increased 19% in the latest quarter. The nine-month revenue-per-subscriber metric increased 33%, indicating higher monetization in addition to customer growth. (2 expanding, 1 shifted)
“Hims & Hers is a consumer-first platform transforming the way customers fulfill their health and wellness needs. Our digital platform enables access to treatments for a broad range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate. Prescriptions are fulfilled online through licensed pharmacies.”
Quarterly Report · Jun 2026 · p.39See how durable this business really is — moats, pricing power, and the cracks.
Growth looks like it is strengthening, led by strong subscriber additions and higher average order values from newer, longer-duration offerings. Revenue rose 52% year over year in the latest quarter, subscribers grew 41% to about 1.7 million, and improved cash generation is helping fund facilities and other expansion. The Zava acquisition also opens several European markets, although its revenue contribution is not yet known. The main risk is the shift away from compounded GLP-1 products, which could raise costs and hurt customer conversion or retention.
Revenue growth is strong and broadly steady, with some acceleration in the latest quarter. Q2 total revenue increased 52% year over year, versus 49% for the first half; online revenue increased 53% in Q2 versus 49% for the first half. Wholesale revenue grew 31% in Q2 versus 44% for the first half, indicating some moderation in that smaller channel. Overall growth is being driven by subscribers, newer offerings, higher average order value, and increased orders. (5 accelerating across 5 signals)
“We generated $131.4 million in Rest of the World Revenue for the three months ended June 30, 2026, an increase of $123.8 million, or 1,641%, as compared to $7.5 million for the three months ended June 30, 2025. Growth in Rest of the World Revenue was primarily driven by the geographic expansion from our recent acquisitions, including our acquisition of Eucalyptus, which closed in the last month of the second quarter of 2026.”
Quarterly Report · Jun 2026 · p.40Capacity expansion is a new, clearly disclosed growth initiative in FY25. Investment accelerated materially: property, equipment, and intangible-asset purchases rose from $17.1 million in 9M FY24 to $166.7 million in 9M FY25, while assets not yet placed in service increased from $33.8 million to $172.6 million. Management expects facility expansion to continue for at least the next 12 months. (1 accelerating, 4 new trend across 5 signals, 3 leading indicators)
“We intend to continue to invest in our fulfillment, distribution, and operating capabilities, including in our wholly-owned pharmacies... our laboratory testing facilities and our peptide manufacturing facility... with the goal of fulfilling a majority of our pharmaceutical and over-the-counter customer orders through internal fulfillment capabilities. For example, we are making investments in the expansion of our current Facilities, which are expected to continue for at least the next 12 months.”
Quarterly Report · Jun 2026 · p.41The cited Eucalyptus acquisition is not present in this filing. The document instead records a July 2025 acquisition of Zava, expanding into the United Kingdom, Germany, France, and Ireland. Because this is the first reported European expansion in the available data, it is a new geographic growth trend, but revenue contribution is not yet disclosed. (4 new trend across 4 signals, 1 leading indicator)
“The Company acquired Eucalyptus to expand its global operations into Australia and Japan and deepen its presence in the United Kingdom, Germany, Ireland, and Canada... On a pro forma basis, giving effect to the acquisition as if it had been completed on January 1, 2025, revenue attributable to Eucalyptus would have represented approximately 15% of the Company’s total consolidated revenue for each of the three and six months ended June 30, 2026.”
Quarterly Report · Jun 2026 · p.12Subscriber growth is strong and accelerating relative to the reported revenue trajectory: subscribers increased 41% year over year to approximately 1.7 million, while monthly revenue per average subscriber was unchanged at $55. The latest quarter therefore shows growth driven primarily by subscriber additions, not higher revenue per subscriber. (3 accelerating, 2 decelerating across 5 signals)
“Subscribers grew 19% to approximately 2.9 million as of June 30, 2026 as compared to approximately 2.4 million Subscribers as of June 30, 2025... Monthly Revenue per Average Subscriber increased $16 to $92 for the three months ended June 30, 2026 as compared to $76 for the three months ended June 30, 2025.”
Quarterly Report · Jun 2026 · p.40A July 2026 agreement gives Hims & Hers access to expertise and technology intended to enable independent manufacturing of certain peptide active ingredients. This could reduce reliance on outside suppliers, but remains milestone-dependent and subject to regulatory and execution risk.
“In July 2026, the Company entered into a one-time agreement with a company in the peptide manufacturing industry to obtain the expertise and technology necessary for the Company to independently manufacture certain peptide active pharmaceutical ingredients in exchange for aggregate cash payments of up to $30.0 million, contingent upon the achievement of certain milestones, and expected to be paid over the next 12 months.”
Quarterly Report · Jun 2026 · p.37Gross margin improved year over year from 80% to 82%, while gross profit increased 49% to $229.1 million on 46% revenue growth. Management attributes the improvement to better provider efficiency, fulfillment-volume synergies, and lower shipping costs as a percentage of revenue. This is a positive margin inflection, although only two annual comparison points are available in the filing. (1 accelerating, 3 reversing, 1 decelerating across 5 signals)
“Our gross margin is expected to remain below comparative periods in the near term, primarily as a result of the 2026 US WL Announcement and recent international acquisitions. While we expect our gross margin to fluctuate from period to period depending on these and other factors, over the long term we expect gross margin to stabilize as we continue to scale our business and increase our ability to negotiate and optimize more favorable costs of revenue, as well as integrate new acquisitions.”
Quarterly Report · Jun 2026 · p.45The largest growth constraint is the regulatory and commercial transition away from broad access to compounded GLP-1 products toward branded medications. The change may increase product costs, reduce conversion or retention, and create supply-chain exposure to branded-drug manufacturers.
“Customers who previously accessed compounded alternatives may be unwilling or unable to transition to branded therapies, which could adversely affect demand, conversion rates, and revenue. In addition, our margins may be impacted by the cost of procuring branded medications and limitations on our ability to pass through price increases. We may also experience operational and financial variability during this transition, including changes in customer behavior, increased churn, or reduced engagement. Further, our reliance on third-party manufacturers and supply chains for branded GLP-1 products exposes us to potential supply disruptions, pricing changes, and contractual limitations outside of our control.”
Quarterly Report · Jun 2026 · p.59See where growth actually comes from — and what's already priced in.
The biggest risks are regulatory and legal pressure around compounded GLP-1 products, marketing, privacy, and consumer protection, along with the possibility that product restrictions reduce customer access. Profitability is also under pressure: costs are rising faster than revenue, gross margin has fallen, and customer acquisition remains expensive. Overall, risk appears to be getting worse, with added debt, acquisition obligations, supply-chain costs, and slower growth increasing the strain. Management is shifting fulfillment to 503A pharmacies, moving toward branded products, and using capped-call protection to limit some potential share dilution, but these steps do not remove the main risks.
Customer acquisition remains expensive and essential to growth. Paid customer acquisition costs increased to $229.5 million in the quarter, and dependence on advertising platforms exposes the company to higher ad prices, algorithm changes, and tighter health-data targeting rules. [DEMAND]
“The most significant component of marketing expenses is customer acquisition costs, which increased to $229.5 million in the three months ended June 30, 2026, compared to $188.4 million for the three months ended June 30, 2025, an increase of $41.1 million.”
Quarterly Report · Jun 2026 · p.50Cash flow quality weakened because operating cash flow depended heavily on non-cash expenses and a large increase in accounts payable. Receivables also rose by $329.0 million, mainly from manufacturer rebates, creating a risk that reported earnings and cash conversion diverge if collections or rebate settlements are delayed. [BALANCE_SHEET]
“This inflow was partially offset by an increase in receivables, net of $329.0 million, which was primarily related to increases in manufacturer’s discount and rebate receivables, an increase in other long-term assets of $30.6 million, an increase in inventory of $14.3 million, and a decrease in earn-out consideration of $7.1 million.”
Quarterly Report · Jun 2026 · p.53Customer acquisition remained a major earnings risk despite strong subscriber growth. Nine-month customer acquisition costs rose 49% to $592.5 million, while marketing expense rose 49% to $681.2 million. Customer acquisition costs represented approximately 34% of nine-month revenue. Management also cited rising advertising rates, privacy restrictions, platform algorithm changes, and changes to health-data targeting as risks. The filing provides no evidence that acquisition efficiency improved; therefore the risk was high and broadly stable-to-worsening. The June 2026 baseline shows the dollar cost continued rising. (3 intensifying, 1 high-severity)
“In recent quarters, there has been a shift towards shorter and more frequent shipping cadences, which has impacted our gross margins. We expect this shift to continue as we enhance our membership program described below.”
Quarterly Report · Jun 2026 · p.40The September 2025 filing showed strong near-term demand: subscribers rose 21% to 2.471 million, online revenue increased 50% in the quarter, and monthly online revenue per average subscriber rose 19% to $80. However, approximately 70% of online revenue came from personalized offerings, many of which may include compounded formulations, while management warned that regulatory restrictions and product availability could reduce customer access. Thus demand was strong at the older period, but concentration in a regulatory-sensitive category made the risk high. The later baseline confirms that the branded-product transition created a more direct demand risk. (5 intensifying, 1 high-severity)
“Customers who previously accessed compounded alternatives may be unwilling or unable to transition to branded therapies, which could adversely affect demand, conversion rates, and revenue. In addition, our margins may be impacted by the cost of procuring branded medications and limitations on our ability to pass through price increases. We may also experience operational and financial variability during this transition, including changes in customer behavior, increased churn, or reduced engagement.”
Quarterly Report · Jun 2026 · p.59The risk was already high in the older September 2025 filing and was worsening operationally: the FDA resolved the semaglutide shortage on February 21, 2025, and its enforcement-discretion period for 503B outsourcing facilities ended May 22, 2025. Hims & Hers stated that it had shifted compounded GLP-1 fulfillment to 503A pharmacies, which constrained use of its 503B facility and could limit supply. Relative to the June 2026 baseline, the later FDA/HHS escalation was not yet disclosed, so this filing shows an earlier, already material regulatory restriction rather than the full later severity. (5 intensifying, 1 high-severity)
“On July 29, 2026, the FTC, along with the Utah Division of Consumer Protection and Los Angeles County on behalf of the People of the State of California, filed a complaint in the United States District Court for the Northern District of California against the Company alleging violations of Section 5 of the FTC Act and certain provisions of ROSCA and analogous state statutes seeking a permanent injunction, monetary relief for an unspecified amount, civil penalties, and other relief as determined by the court. ... As of June 30, 2026, the Company had recorded a legal contingency accrual of approximately $60 million for this matter in accordance with ASC 450, Contingencies.”
Quarterly Report · Jun 2026 · p.29This was an identifiable and worsening sub-risk within the September 2025 filing. Management specifically attributed lower gross margin to newer offerings with shorter shipping cadences and higher fulfillment costs. For the nine months, shipping costs increased 70%, while product and packaging costs increased approximately 179%. The company stated that personalized offerings were becoming a larger share of revenue, increasing exposure to this cost structure. The June 2026 baseline shows the pressure continued and became more severe. (1 intensifying, 1 high-severity)
“Certain of our weight loss offerings are primarily fulfilled by one supplier. If this supplier stops fulfilling purchase orders, it could significantly slow our ability to fulfill these orders until new suppliers are identified and fully onboarded and/or our internal manufacturing capabilities are expanded.”
Quarterly Report · Jun 2026 · p.73The risk was clearly intensifying within the filing's year-over-year comparison. For the nine months ended September 30, 2025, cost of revenue increased 130% while revenue increased 74%; gross margin fell to 75% from 81%. In the third quarter, cost of revenue rose 88% versus 49% revenue growth and gross margin fell to 74% from 79%. Operating expenses rose 46% in the quarter and 57% year to date, causing quarterly operating income to decline 47% to $11.8 million. Compared with the June 2026 baseline, the later deterioration was substantially worse, but the adverse direction was already evident here. (4 intensifying, 1 high-severity)
“Cost of revenue was $272.4 million for the three months ended June 30, 2026, compared to $128.6 million for the three months ended June 30, 2025, an increase of $143.8 million, or 112%. ... Gross margin was 64% for the three months ended June 30, 2026, compared to 76% for the three months ended June 30, 2025.”
Quarterly Report · Jun 2026 · p.49The filing shows a meaningful regulatory and litigation overhang, but provides no quantified reserve or outcome for the FTC matter. It discloses an FTC Civil Investigative Demand from October 2023 and says the investigation remained unresolved. The company also acknowledged claims concerning tracking technologies and risks involving marketing, subscriptions, privacy, and consumer protection. Because the June 2026 baseline reports subsequent lawsuits and approximately $60 million accrued, the risk materially worsened after this filing; for the September 2025 period itself, severity was already high but not yet quantified. (3 intensifying, 1 emerging, 5 high-severity)
“Additionally, in February 2026, we received a letter from the staff of the Securities and Exchange Commission, Division of Enforcement, notifying us that it had opened an investigation and requesting that we preserve certain documents and information concerning our public statements and disclosures regarding compounded semaglutide and related business relationships (the “SEC Investigation”). We are cooperating with the SEC Investigation but are unable to predict when or how this matter will be concluded, including any financial impact.”
Quarterly Report · Jun 2026 · p.75See the risks that could break this thesis.
Want this thesis on a stock you own?
Create a free account to prefill a ticker and generate the same cited management, growth, risk, and scenario analysis.
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.